Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Nemtabrutinib in Participants With Moderate Hepatic Impairment
NCT06442436Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of nemtabrutinib in hematologic malignancy (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Curve from Dosing to Infinity at 336 hours and Maximum Concentration at 336 hours. Started Jul 2024; status: completed.
02
Drugs
nemtabrutinib
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT06442436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06442436.